摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

三(2-苯基苯基)亚磷酸酯 | 2752-19-4

中文名称
三(2-苯基苯基)亚磷酸酯
中文别名
——
英文名称
tris(2-phenylphenyl)phosphite
英文别名
Tris(2-phenylphenyl)phosphit;tris-phenylphenyl phosphite;Tri-2-biphenyl-phosphit;tris ortho xenyl phosphite;tris(2-biphenylyl)phosphite;Phosphorigsaeure-tris-biphenyl-2-ylester;phosphoric acid tris-biphenyl-2-yl ester;tris[(1,1'-biphenyl)-2-oxy]phosphine;Tris-(biphenylyl-(2))-phosphit;tri(2-phenylphenyl)phosphite;tri-(O-phenyl phenyl)-phosphite;tris(o-phenylphenyl) phosphite;(1,1'-Biphenyl)-2-ol, phosphite (3:1);tris(2-phenylphenyl) phosphite
三(2-苯基苯基)亚磷酸酯化学式
CAS
2752-19-4
化学式
C36H27O3P
mdl
——
分子量
538.582
InChiKey
DAZUWKNHFLGZSN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    93°C
  • 沸点:
    654.0±54.0 °C(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    10.4
  • 重原子数:
    40
  • 可旋转键数:
    9
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    27.7
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2919900090

SDS

SDS:011a4b99c50b13b22b2b4ef210134704
查看
Name: Tris Ortho Xenyl Phosphite 95% Material Safety Data Sheet
Synonym: (1,1' Biphenyl)-2-Ol; Phosphite (3:1)
CAS: 2752-19-4
Section 1 - Chemical Product MSDS Name:Tris Ortho Xenyl Phosphite 95% Material Safety Data Sheet
Synonym:(1,1' Biphenyl)-2-Ol; Phosphite (3:1)

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
2752-19-4 Tris Ortho Xenyl Phosphite 95% 220-396-0
Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Hygroscopic (absorbs moisture from the air).
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation. Use with adequate ventilation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Keep refrigerated. (Store below 4C/39F.) Store protected from moisture.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2752-19-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 95.00 - 98.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: may decompose
Specific Gravity/Density:
Molecular Formula: C36H27O3P
Molecular Weight: 538.59

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants, exposure to moist air or water.
Incompatibilities with Other Materials:
Moisture, oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of phosphorus, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2752-19-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Tris Ortho Xenyl Phosphite - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 2752-19-4: No information available.
Canada
CAS# 2752-19-4 is listed on Canada's NDSL List.
CAS# 2752-19-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2752-19-4 is listed on the TSCA inventory.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    三(2-苯基苯基)亚磷酸酯 在 zinc(II) chloride 、 三氯化磷 作用下, 反应 4.0h, 以35 g的产率得到10-氯-9,10-二氢-9-氧杂-10-磷杂菲
    参考文献:
    名称:
    一种9,10-二氢-9-氧-10-磷杂菲-10-氧化物 的合成方法
    摘要:
    本发明公开了一种9,10‑二氢‑9‑氧‑10‑磷杂菲‑10‑氧化物的合成方法;该方法是将三氯化磷滴加到过量邻苯基苯酚中进行酯化反应,得到亚磷酸三邻苯基苯酯;在所述亚磷酸三邻苯基苯酯中加入ZnCl2催化剂,滴加三氯化磷进行酰化反应,得到6‑氯‑(6氢)‑二苯并‑(c,e)‑氧磷杂己环;所述6‑氯‑(6氢)‑二苯并‑(c,e)‑氧磷杂己环依次进行水解反应和环化反应,即得;该方法避免了邻苯基苯酚在高温下挥发和氧化,且反应速度快,目标产物的产率和纯度高,适合工业生产。
    公开号:
    CN105949242B
  • 作为产物:
    描述:
    邻苯基苯酚2,3-二甲基苯胺三氯化磷 作用下, 以 xylene 为溶剂, 以40%的产率得到三(2-苯基苯基)亚磷酸酯
    参考文献:
    名称:
    镍催化异戊二烯区域选择性环二聚的机理
    摘要:
    对各种Ni-配体催化的异戊二烯低聚的研究表明,使用π-酸性P配体,对环二聚体的选择性达97%。引入了一种新型的配体,即。具有与-PCl 3相当的π-受体特性的亚磷酸氟烷基酯。亚磷酸三(六氟异丙基)酯的主要产物是1,4-二甲基1-4-乙烯基环己烯。给出了基于两步机制的详细说明。关于第一步,对于一系列具有相似空间特性的配体,根据Ni和烯烃之间HOMO-LUMO相互作用的逐渐变化(具有很强的π)解释了产物分布随电子配体参数变化的变化。 -酸性配体促进异戊二烯分子的头对头偶联。第二步涉及从金属中还原性消除环二聚体,显示出随着配体的π-酸度增加,对头对头和尾对尾中间体对取代的环己烯的选择性增加。
    DOI:
    10.1016/s0040-4020(01)97949-9
  • 作为试剂:
    描述:
    环亚丙基环丙烷富马酸二乙酯bis(1,5-cyclooctadiene)nickel (0) 三(2-苯基苯基)亚磷酸酯 作用下, 以 甲苯 为溶剂, 反应 0.83h, 生成 、 、 diethyl (1S,2R)-3-[(3R,4R)-3,4-bis(ethoxycarbonyl)cyclopentylidene]cyclopentane-1,2-dicarboxylate
    参考文献:
    名称:
    钯(0)-和镍(0)-催化的双环亚丙基与烯烃的[3+2]共环化反应
    摘要:
    双环亚丙基 (1) 很容易与缺电子烯烃(丙烯酸甲酯、反式巴豆酸甲酯、肉桂酸甲酯和富马酸二乙酯)以及一些紧张的烯烃(降冰片烯、降冰片二烯)通过远端环裂解 1 的三元环之一。所有这些共环化对 1 都是区域选择性的,并且对烯烃具有区域和立体选择性,得到相应的 4-亚甲基螺[2.4]具有缺电子烯烃的庚烷-反式-6-羧酸盐 2a-5 和带有应变烯烃的环加合物 6 和 7 以可接受的良好收率(56% 至 83%)。与钯 (0) 催化剂相反,当 1 与例如反应时,镍 (0) 配合物催化 1 的远端开环和两个双键的氧化偶联。富马酸二乙酯。结果是亚甲基环戊烷衍生物 5 与 [2 + 2] 环加合物 8 和共三聚体 9 的混合物。
    DOI:
    10.1002/(sici)1099-0690(199801)1998:1<113::aid-ejoc113>3.0.co;2-1
点击查看最新优质反应信息

文献信息

  • Orthopalladated phosphinite complexes as high-activity catalysts for the Suzuki reaction
    作者:Robin B. Bedford、Samantha L. Hazelwood (née Welch)、Peter N. Horton、Michael B. Hursthouse
    DOI:10.1039/b303657j
    日期:——
    phosphinite ligands PR2(OAr) (R = Ph, iPr), their simple complexes with palladium(II) and their palladacyclic complexes has been investigated. The crystal structure of one of the palladacyclic complexes, [Pd(μ2-Cl)κ2-P,C-PiPr2(OC6H2-2,4-tBu2)}2], has been determined. The palladacyclic complexes show extremely high activity in the Suzuki coupling of aryl bromide substrates with phenylboronic acid and can
    一系列次膦酸酯的合成 配体PR 2(OAr)(R = Ph,i Pr),它们与(II)的简单配合物及其环配合物已得到研究。所述palladacyclic络合物中的一个的晶体结构,[的Pd(μ 2 -Cl)κ 2 - P,Ç -P我2(OC 6 H ^ 2 -2,4-吨卜2)} 2 ],有被确定。Palladacyclic配合物在芳基化物底物与Suzuki偶联的Suzuki偶联中显示出极高的活性苯硼酸还可与烷基硼酸底物一起使用。次膦酸酯基的比较催化剂与基于亚磷酸酯和膦的体系相当的产品突显了其卓越的活性。次膦酸酯的原属化配体在预催化剂中似乎对于最佳活性至关重要。尽管次膦酸酯四环化合物仅在活化和未活化的芳基化物底物的偶联中具有中等活性,但它们的三环己基膦 加合物在失活的底物偶联中被证明具有很高的活性, 4-茴香醚。与其他四环系统相比,这种高活性的解释是:催化剂长寿。原属化的预
  • METHOD FOR PRODUCING ALDEHYDE COMPOUND, AND ACETAL COMPOUND
    申请人:KURARAY CO., LTD.
    公开号:US20170369411A1
    公开(公告)日:2017-12-28
    Provided are a method for producing 3-methylglutaraldehyde in a good yield under a mild condition and a novel acetal compound which is useful for carrying out the foregoing method. The method is a production method of 3-methylglutaraldehyde including a step of hydrolyzing a compound represented by the following general formula (1): wherein R 1 and R 2 each independently represent an alkyl group having 1 to 6 carbon atoms, or are mutually coupled to represent an alkylene group having 2 to 6 carbon atoms.
    提供了一种在温和条件下高产率生产3-甲基戊二醛的方法,以及一种新型缩醛化合物,该化合物对于执行上述方法是有用的。该方法是一种生产3-甲基戊二醛的方法,包括以下一步骤:解由下述通式(1)表示的化合物:其中R1和R2各自独立地表示具有1至6个碳原子的烷基基团,或者相互偶合以表示具有2至6个碳原子的亚烷基基团。
  • Transition metal allyls
    作者:R. Benn、B. Büssemeier、S. Holle、P.W. Jolly、R. Mynott、I. Tkatchenko、G. Wilke
    DOI:10.1016/0022-328x(85)87007-8
    日期:1985.1
    Butadiene and methyl substituted 1,3-dienes react with zerovalent-nickel-ligand complexes in a stoichiometric manner to give octadienediylnickel-ligand complexes. The structure, rearrangement and reactions with CO and P-donor ligands of these species have been studied with the help of 1H and 13C NMR spectroscopy. The results provide an insight into the mechanism of the nickel-catalysed cyclodimerization
    丁二烯和甲基取代的1,3-二烯以化学计量的方式与零价-配体络合物反应,生成辛二烯二基-配体络合物。借助1 H和13 C NMR光谱研究了这些物种的结构,重排以及与CO和P供体配体的反应。该结果提供了对催化的1,3-二烯环二聚反应机理的见解。
  • Asymmetric induction in carboncarbon bond forming reactions of prochiral nucleophiles with electrophiles containing chiral iron centers
    作者:John E. Jensen、Lynnette L. Campbell、Saburo Nakanishi、Thomas C. Flood
    DOI:10.1016/s0022-328x(00)98633-9
    日期:1983.3
    diastereomeric resonances in their NMR spectra. Product ratios from alkylation by acetoacetate were thermodynamic, while those from alkylation by the enamine were presumed to be kinetic. The excess of one diastereomer over the other, relating in principle to an “optical yield” at the new chiral carbon center induced by the existing metal chirality, ranged from 10 to 64% depending on the nucleophile and the electrophile
    手性亲电体烷基化CpFe的量(CO)(L)CH 2 Cl和CpFe的量(CO)(L)(CH 2 CH 2)+ SO 3 CF 3 -(L = PPH 3和三(ö联苯基)亚磷酸酯)由前手性亲核试剂乙酰乙酸叔丁酯吡咯环己酮烯胺产生了八种可能的烷基产物中的六种。L是o的两个产品亚磷酸联苯酯和乙酰乙酸叔丁酯没有形成亲核试剂,大概是因为空间位阻过大。在每种情况下形成的两种非对映异构体的相对量可从其NMR光谱中的非对映异构体共振轻松确定。通过乙酰乙酸烷基化得到的产物比率是热力学的,而通过烯胺的烷基化得到的产物比率被认为是动力学的。一种非对映异构体相对于另一种非对映异构体的过量,原则上与现有属手性引起的在新手性碳中心的“光学收率”有关,介于10%到64%之间,具体取决于亲核试剂和亲电试剂,但最明显的是,配体L.
  • Process for the preparation of acid esters
    申请人:General Electric Company
    公开号:US20040059151A1
    公开(公告)日:2004-03-25
    The present invention is directed to a process for the preparation of sterically hindered acid esters, e.g., organic phosphites, comprising contacting a sterically hindered hydroxyl-containing compound with an acid halide in the presence of an acid acceptor selected from the group consisting of: 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 4-(dimethylamino)pyridine (DMAP), 1,4-diazabicyclo[2.2.2]octane (DABCO), or mixtures thereof, wherein said an acid acceptor is present in an amount sufficient to drive the reaction to completion.
    本发明涉及一种制备立体位阻酸酯的方法,例如有机磷酸酯,包括将立体位阻羟基化合物与酸卤在酸受体的存在下接触,所述酸受体选自以下组中的一种:1,5-二氮杂双环[4.3.0]壬-5-烯(DBN)、1,8-二氮杂双环[5.4.0]十一烷-7-烯(DBU)、4-(二甲氨基吡啶DMAP)、1,4-二氮杂双环[2.2.2]辛烷DABCO)或其混合物,其中所述酸受体的存在量足以将反应推向完成。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫